Methods and kits for diagnosing or monitoring synovial or osteoarticular disease, comprising the use of a specific marker for synovial tissue degradation
AssigneeInstitut National de la Sante et de la Recherche Medicale
InventorsPierre Delmas, Patrick Garnero, Evelyne Gineyts
Life of this patent
Estimating the term…
Abstract
Disclosed are specific markers for synovial tissue degradation and methods of using the markers in diagnosing, monitoring or determiing a prognosis of synovial disease.
Claims31
A method for diagnosing or monitoring the evolution of a synovial disease, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing the absence of the disease or representing a predetermined stage in the disease, the level of the marker with respect to the reference level indicating the presence of or evolution of the synovial disease.
A method for monitoring the evolution of an osteoarticular disease, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing a predetermined stage in the disease, the level of the marker with respect to the reference level indicating the evolution of the synovial disease.
A method for determining a prognosis of evolution towards an osteoarticular disease or towards a predetermined stage in osteoarticular disease, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level and deducing a prognosis of evolution towards an osteoarticular disease or towards a stage in osteoarticular disease from that comparison.
A method for determining the efficacy of a drug administered to an individual for the treatment of an osteoarticular disease, comprising:
- i) bringing a biological sample from an individual under treatment into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing a predetermined stage of the disease, the level of the marker with respect to the reference level indicating the evolution of the synovial disease, and therefore the degree of efficacy of the treatment.
A method for determining the toxicity associated with an osteoarticular or synovial disease of a drug intended to treat a disease, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing the presence of or a predetermined stage in the disease, the level of the marker with respect to the reference level indicating the degree of disease and therefore the degree of toxicity associated with a synovial or osteoarticular disease.
A method for early diagnosis of an osteoarticular disease, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing the presence of or a predetermined stage of the disease, the level of the marker with respect to the reference level indicating the actual or potential presence of synovial disease.
A method for diagnosing or monitoring synovial collagen degradation, comprising:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker for synovial disease;
- ii) determining the level of the specific marker;
- iii) optionally, comparing the level of the marker with a reference level representing the base or normal level for synovial collagen degradation, the level of the marker with respect to the reference level indicating normal or pathological degradation.
A method for possible early diagnosis or for monitoring the evolution of an osteoarticular disease involving the degradation of synovial disease, characterized by:
- i) bringing a biological sample from an individual into contact, in vitro, with a means for measuring a specific marker the level of which alone reflects the degree of synovial collagen degradation;
- ii) determining the level of the specific marker.
A kit for diagnosing or monitoring the evolution of a synovial disease, comprising at least one means for measuring a specific marker for synovial disease and a mention of the reference level representing the absence of the disease or representing a predetermined stage of the disease.
A kit for diagnosing or monitoring the evolution of an osteoarticular disease, comprising at least one means for measuring a specific marker for synovial disease and a mention of the reference level representing the absence of the disease or representing a predetermined stage in the disease.
A kit for determining a prognosis of evolution towards an osteoarticular disease or towards a stage in osteoarticular disease, comprising at least one means for measuring a specific marker for synovial disease and a mention of the reference level representing the prognosis.
A kit for determining the efficacy of a drug administered to an individual for the treatment of an osteoarticular disease, comprising at least one means for measuring a specific marker for synovial disease and a mention of a reference level representing a degree of efficacy of said drug.
A kit for determining the toxicity of a drug intended to treat a disease, comprising at least one means for measuring a specific marker for synovial disease and a mention of a reference level representing a level of toxicity for said drug.
An antibody that can specifically recognise glucosyl-galactosyl-pyridinoline.
Dependencies are inferred from the claim text.